Mode
Text Size
Log in / Sign up
N/A N=56 Randomized Treatment

Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)

Insomnia · Insomnia Due to Medical Condition · Cancer

Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Insomnia Severity Change at 8 Weeks — 7.25; 5.67 Units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
STEP-YA with Coaching (Behavioral); STEP-YA without Coaching (Behavioral)
Age
Adult · 20+ yrs
Sex
All
Sponsor
Dana-Farber Cancer Institute
Primary completion
Jul 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Insomnia Severity Change at 8 Weeks
7.25; 5.67
SECONDARY
Profile of Mood States Change at 8 Weeks
4.07; 7.75
SECONDARY
Profile of Mood States Change at 4 Weeks
9.48; 12.00
SECONDARY
Insomnia Severity Change at 4 Weeks
9.51; 8.28

Summary

The purpose of the study is to learn if a single online education session, with or without individualized coaching sessions, can help improve young adult cancer survivors' (YACS) sleep. The name of the study intervention is Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA).

Eligibility Criteria

Inclusion Criteria

To be determined by patient self-report from eligibility screening with potential participants. (See Appendix A for eligibility screening materials). Participants must be screened for eligibility ≤2 weeks prior to study enrollment. Participants who are screened earlier must be rescreened within this period.

  • Age 20-39
  • History of a cancer diagnosis (except non-melanoma skin cancer) ≥ 1 year prior
  • No active cancer therapy (excluding chemoprevention) in the past four months, and no further therapy planned
  • Significant insomnia as evidenced by an Insomnia Severity Index score ≥12
  • Able to read and write in English

Exclusion Criteria

  • Survivors who report ever being diagnosed with Bipolar Disorder.
  • Survivors who report ever being diagnosed with a Seizure Disorder or have experienced a seizure in the past 12 months.
  • Intention to adjust (decrease or increase) use of any prescribed or over-the-counter medications taken to decrease insomnia during the study period.
  • Survivors who report being diagnosed with sleep apnea who are not receiving recommended medical treatment for their sleep apnea (as assessed by screening questions, see Appendix A).
  • Survivors who report suspected sleep apnea who have not completed an evaluation by a sleep specialist (as assessed by screening questions, see Appendix A).
  • Survivors who report their usual bedtime does not fall between 5:00 pm and 5:00 am.
  • Employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel across time zones, or employment in a position that could impact public safety (such as air traffic-controller, operating heavy machinery)
  • Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently.
  • Prior participation in a research study which provided an educational or behavioral intervention for insomnia
  • Prior participation in a behavioral treatment or patient education program for insomnia delivered at the Dana-Farber Cancer Institute, or at Boston Children's Hospital.
  • Participation in behavioral or educational interventions for insomnia in the 2 years prior to enrollment. This includes in-person as well as synchronous and asynchronous online insomnia programs, but not independent use of books, workbooks or other written self-help materials addressing insomnia.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05358951). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search